Skip to main content
Premium Trial:

Request an Annual Quote

Chicago Scientists Launch Expression-Analysis Service Firm

NEW YORK, April 4 (GenomeWeb News) - Four scientists from the Children's Memorial Research Center in Chicago have launched Precision Biomarker Resources, a CRO that will provide microarray processing and data-analysis services to pharmaceutical, biotechnology, and academic researchers.


The new company, based in Evanston, Ill., is an Affymetrix-authorized service provider and will use Affy's GeneChip platform as part of its services.


As originally reported in GenomeWeb News' sister publication BioArray News last week, Precision Biomarker Resources was founded by scientists who established the Pediatric Brain Tumor Research Program at Children's. They are David Paul, who will serve as president; Eric Bremer, chief scientific officer; Jason Monroe, director of operations; and David George, director of bioinformatics.


The fifth founder is Charles Happ, who will serve as Precision's business director, and is currently board chairman of the Technology Innovation Center incubator based in Evanston.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.